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PURPOSE: To study the indications and results of tacrolimus as rescue therapy for acute cellular or chronic rejection
in liver transplantation.
PATIENTS AND METHODS: Eighteen liver transplant recipients who underwent rescue therapy with tacrolimus
between March 1995 and August 1999 were retrospectively studied. The treatment indication, patients, and graft situation
were recorded as of October 31st, 1999. The response to tacrolimus was defined as patient survival with a functional graft and
histological reversal of acute cellular, or for chronic rejection, bilirubin serum levels decreasing to up to twice the upper
normal limit.
RESULTS: Fourteen cases (77.8%) presented a good response. The response rate for the different indications was: (1)
acute cellular + sepsis - 0/1 case; (2) recurrent acute cellular - 1/1 case; (3) OKT3-resistant acute cellular - 2/2 cases; (4)
steroid–resistant acute cellular + active viral infection - 3/3 cases; (5) chronic rejection - 8/11 cases (72.7% response rate).
The 4 patients who did not respond died.
CONCLUSION: Tacrolimus rescue therapy was successful in most cases of acute cellular and chronic rejection in liver
transplantation.
DESCRIPTORS: Liver transplantation. Adverse effects. Immunosuppression. Tacrolimus. Therapeutic use.
After the advent of cyclosporin in
1980, the survival rate of patients un-
dergoing liver transplantation (LTx)
improved dramatically1. At our unit,
cyclosporin in combination with aza-
thioprine and corticosteroids consti-
tutes the drug of choice for immunosup-
pressive therapy in LTx. With this thera-
peutic regimen, about 30% of the pa-
tients undergoing LTx presented epi-
sodes of acute cellular rejection (ACR)2.
Recent studies have shown that up to
13% of the episodes of ACR are refrac-
tory to the standard treatment with
corticosteroids3. For this reason, ACR
continues to be a cause of graft loss4-6.
The most widely used agent in the
treatment of steroid-resistant ACR is
OKT3, a monoclonal antibody that
blocks lymphocyte-mediated cytotox-
icity by binding with the CD3
receptor7. However, its use is limited
by adverse reactions, by an increased
occurrence of opportunistic infectious
diseases, and by lymphoproliferative
disorders, as well as the high cost8,9.
More recently, tacrolimus (FK506)
made its appearance as an alternative
immunosuppressive drug. It became
available in Europe in 1990.10 FK506
is a macrolide compound isolated from
Streptomyces tsukubaensis and has an
immunosuppressive potential approxi-
mately 100 times more powerful than
cyclosporin11,12. The drug acts by bind-
ing to cytoplasmic proteins of the
lymphocytes, primarily FKBP12, form-
ing a complex that associates with
calcineurin. Some direct or indirect
substrates of calcineurin act as tran-
scription factors and promote the acti-
vation of genes that encode cytokine
production.
This activation is dependent on the
calcium influx into the cell. The asso-
ciation of calcineurin to the FK506
complex prevents stimulatory signal
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Figure 1 - Liver biopsy showing the loss of small bile ducts in the portal tract. Note the
deposition of hemosiderin in hepatocytes and macrophages.
Table 1 - Indications for liver
transplantation in patients undergoing
rescue therapy with tacrolimus for acute
and chronic rejections.
Indications n
primary sclerosing cholangitis 4
hepatitis C cirrhosis 4
acute liver failure 2
ductopenic disease 1
primary biliary cirrhosis 1
alcoholic cirrhosis 1
cryptogenic cirrhosis 1




transduction, inhibiting the formation
of interleukin-2 by the T-lymphocytes
and the formation of other soluble me-
diators, such as interleukin-3 and in-
terferon-γ 11,12.
The introduction of FK506 has
added an alternative to OKT3 for res-
cue therapy of steroid-resistant ACR. It
also has opened new possibilities for
the pharmacological control of chronic
liver graft rejection (CR), which until
that time, was treated exclusively by
retransplantation13.
The purpose of this study was to
analyze the indication criteria and the
results of employing FK506 in rescue
therapy of acute and chronic rejection
in LTx.
PATIENTS  AND  METHODS
All 244 LTx performed at our unit
between March 1995 and August 1999
were retrospectively studied. Among
these, we identified and analyzed 7
cases of ACR and 11 cases of CR that
had been converted to FK506 for res-
cue therapy.
Eight of the 18 patients who under-
went rescue therapy with FK506 were
males. The mean age was 39.1 ± 15.4
years (16 to 64 years). The indications
for LTx for these patients are shown in
table 1.
The primary immunosuppressive
therapy for all patients was based on
cyclosporin, prednisone, and azathio-
prine, according to the standard serv-
ice protocol. According to this regi-
men, 1 g of methylprednisolone was
delivered intravenously at the time of
revascularization, and 200 mg of pred-
nisone or methylprednisolone were
delivered on the immediate postopera-
tive day (PO). This dosage was tapered
to 40 mg/day until the maintenance
dosage of 20 mg/day was achieved on
the sixth PO. Azathioprine was admin-
istered orally, at a daily dosage of 1
mg/kg. Cyclosporin was introduced
orally between the first and third PO,
10 mg/kg, divided into 2 daily doses.
The dosage was adjusted daily to
achieve a target trough blood level
between 300 and 350 ng/mL
(monoclonal TDX). During the first
year PO, the dosage of cyclosporin was
progressively reduced to attain a
trough blood level of approximately
100 ng/mL. During the same period,
the dosage of prednisone was reduced
to 5 mg/day. ACR episodes were
treated with 1 to 3 pulses of 1 g of
methylprednisolone, followed by a 6-
day taper from 200 to 20 mg/day.
Rescue therapy with FK506 was
individualized in each case. Only the
oral formulation of FK506 was used.
The initial dosage ranged from 0.1 to
0.3 mg/kg/day, and was adjusted ac-
cording to the trough blood level. Ini-
tially the target blood level was main-
tained around 15 ng/mL. However, the
target level was set on an individual
basis according to the patient’s clini-
cal response and the severity of the
side effects. One month after conver-
sion, the mean dosage of FK506 was
0.2 ± 0.1 mg/kg/day. During this pe-
riod, the mean blood level was 13.8 ±
5.9 ng/mL. Corticosteroid administra-
tion was maintained in all cases. Five
patients received combination therapy
with mycophenolate mofetil (MMF) in
dosages ranging from 1.0 to 3.0 g/day.
The diagnosis of ACR and CR was
suspected because of clinical and labo-
ratory alterations. All ACR episodes
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Figure 2 - Liver biopsy showing degenerative alterations in the interlobular bile ducts (arrow).
Note the cytoplasmic eosinophilia, the nuclear pyknosis, and the absence of portal inflammation.
Figure 3 - Angiographic study of the liver graft showing multiple arterial strictures.
were histologically confirmed. The 11
diagnoses of CR were established us-
ing one of the following three criteria:
1- characterization of ductopenia in
liver biopsy14, in 5 patients (Fig. 1); 2-
presence of bile duct damage in the bi-
opsy,14 with normal cholangiography
and hepatic angiography, in 5 cases
(Fig. 2); 3- presence of duct aggression
with angiographic demonstration of
multiple intrahepatic arterial strictures
in 1 case (Fig. 3).
Steroid-resistant ACR was defined
as the persistence of the clinical, bio-
chemical, and histopathological signs
of rejection after treatment with at
least 2 pulses of 1.0 g of methylpred-
nisolone. OKT3-resistant ACR was de-
fined as the persistence of the clinical,
biochemical, and histopathological
signs of rejection after treatment with
the drug for at least 10 days.
In the 18 cases studied, the follow-
ing data were recorded: date of LTx,
indication for rescue therapy, date of
conversion, follow-up period, and pa-
tient and graft situation on October
31st, 1999.
The response to FK506 was de-
fined as patient survival with func-
tional graft and histological reversal
of ACR, or for CR, bilirubin serum lev-
els decreasing to up to twice the up-
per normal limit.
The patients’ actuarial survival
rates were calculated using the Kaplan-
Meier method.
RESULTS
Five different indications for rescue
therapy with FK506T were identified:
1) ACR plus bacterial sepsis (n=1); 2)
recurrent ACR (n=1); 3) OKT3-resist-
ant ACR (n=2); 4) steroid-resistant
ACR plus active viral disease (n=3); 5)
chronic rejection (n=11).
The patient with recurrent ACR
presented 4 rejection episodes in a 4-
month period. Among the 3 patients
with ACR plus active viral disease, 2
presented cytomegalovirus (CMV)
hepatitis, and 1 had herpetic
gastroenterocolitis.
Table 2 shows the response rate to
FK506 for each indication. Fourteen
patients (77.8%) were considered “pa-
tients who responded”. All 4 patients
with no response died. The mean fol-
low-up time after conversion to FK506
was 19.8 months, ranging from 10
days to 48 months.
The 47-month actuarial survival
rates were up to 61.5% in cases of CR
(Fig. 4). Figures 5, 6, and 7 show the
evolution of the serum levels of total
bilirubin, alkaline phosphatase, and
alanine transaminase (ALT) during the
first 12 months of treatment with
FK506.
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Table 2 - Results: indication for conversion to tacrolimus, percentage of response
and mean follow-up.
Indication for conversion to tacrolimus n Response Mean follow up
(months)
ACR + bacterial sepsis 1 0 0.3
Recurrent ACR 1 1 2.0
OKT3-resistant ACR 2 2 43.5 (39-48)
Steroid-resistant ACR + viral infection 3 3 39.3 (31-46)
Chronic rejection 11 8 (72.7%) 13.5 (0.5-47)
Total 1 8 14 (77.8%) 19.8 (0.3-48)
ACR= acute cellular rejection.
Figure 4 - Actuarial survival of the 11 patients with chronic rejection
of the liver graft undergoing rescue therapy with tacrolimus.
Figure 6 - Evolution of alkaline phosphatase serum levels in patients
undergoing rescue therapy with tacrolimus for treatment of chronic
rejection of the liver graft. The upper normal limit of alkaline
phosphatase is 223 U/L.
Figure 5 - Evolution of total bilirubin serum levels in patients
undergoing rescue therapy with tacrolimus for the treatment of chronic
rejection of the liver graft. The upper normal limit of total bilirubin is
1.3 mg/dL.
Figure 7 - Evolution of alanine aminotransferase serum levels in
patients undergoing rescue therapy with tacrolimus for treatment of
chronic rejection of the liver graft. The upper normal limit of alanine
aminotransferase is 32 U/L.
DISCUSSION
Several clinical studies have evalu-
ated the effects of FK506 on rescue
therapy of CR or ACR in LTx recipi-
ents15. Most have demonstrated the
beneficial effects of the drug, with a
success rate of up to 89% for steroid-
resistant ACR16.
Sher et al.17 obtained a response
rate of 70.3% in patients with CR,
while Platz et al.16 reported a success
rate of 88.9% in patients with steroid-
resistant ACR. In the present study, the
response rate was 72.7% and 85.7% in
cases of CR and ACR, respectively.
In the present study, the survival
rate of the patients undergoing rescue
therapy for CR was 61.5% at 2 years
(Fig. 4). Sher et al.17 observed an
81.2% survival rate with the same fol-
low-up, while Jonas et al.5 obtained a
76% survival rate.
In the present study, only 3 pa-
tients (16.7%) were less than 18 years
old; the youngest patient was 16. Thus,
our results refer basically to an adult
population. Other authors, however,
have shown positive long-term results
with FK506 rescue therapy for
pediatric patients. Reyes et al. 18,
studying pediatric LTx recipients, ob-
tained a patient survival rate of 78.1%
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and 74.6% at the 5- and 8-year follow-
up, respectively. In the cases converted
due to ACR (95.5% survival at 8
years), results were better than for cases
of CR (74.6%).
Considering the positive efficacy of
FK506, some authors propose it as the
drug of choice for steroid-resistant ACR
to avoid the use of anti-lymphocyte an-
tibodies11,12. Some studies have shown
that the need for retransplantation is
more marked in patients undergoing
OKT3 rescue therapy (15.8%) than in
patients treated with FK506 (5.5%)16.
Thus, the indication for OKT3 for ster-
oid-resistant ACR has been restricted,
and its use has declined in several trans-
plant centers16.
There are some prognostic factors
related to the therapeutic success rate
of FK5065,17. Jonas et al.5, studying pa-
tients with ACR, found a significant
lower bilirubin level prior to the con-
version in patients who responded (12.0
± 5.6 mg% vs. 29.7 ± 5.9 mg%; P <
0.05). Sher et al.17 identified 2 inde-
pendent prognostic factors in patients
with CR: total bilirubin and the time
elapsed between LTx and conversion.
The cases of total bilirubin greater than
10 mg/dL presented a 13.8% 2-year
graft survival, compared to 86.0% for
patients with a level below this value.
Patients converted up to 90 days after
LTx had a graft survival of 51.9% com-
pared to 87.7% for patients converted
later. In the present study, the bilirubin
level was correlated with a similar ef-
fect in patients with CR. Two of the 3
patients who died presented a total pre-
conversion bilirubin level higher than
10 mg/dL. Inversely, only 2 of the 8 pa-
tients who responded presented a bi-
lirubin level above this value. The me-
dian time elapsed between LTx and the
beginning of the rescue therapy was
127 days for patients who did not re-
spond (range 64 to 536 days), and 146
days for patients treated successfully
(range 27 to 836 days).
Similarly to other studies17,18, the
criteria used to determine a positive
response in CR were based only on
clinical and biochemical data. It
would, however, be interesting to
clarify the effect of the conversion to
FK506 on the histological and angio-
graphic alterations found initially. Un-
fortunately this information was not
available, since the patients who re-
sponded did not undergo control bi-
opsies or angiographies. Perhaps the
question can be clarified in a prospec-
tive study about rescue therapy of CR.
Regarding the biochemical evolu-
tion, Sher et al.17 described a signifi-
cant drop in mean bilirubin levels in
the group of patients who responded,
from 7.1 mg/dL prior to conversion to
3.4 mg/dL after 2 years. In patients
who did not respond the mean bi-
lirubin level was 19.8 mg/dL at the
time of conversion, and remained 14.0
mg/dL at the time of retransplan-
tation17. Similarly, ALT was also indi-
cated as a prognostic factor, presenting
a significantly larger reduction in pa-
tients who responded17. In the present
study, mean total bilirubin and ALT
levels dropped progressively during
treatment with FK506 (Figs. 5 and 7).
A similar profile was observed with al-
kaline phosphatase levels (Fig. 6). De-
spite the biochemical response, the
median values of these enzymes were
approximately twice the upper normal
limit 12 months after conversion.
MMF was combined with FK506
in 5 patients because of different rea-
sons and at variable periods. In 2 cases
of CR, MMF was given due to FK506
nephrotoxicity. The first patient began
MMF therapy 1 month after conver-
sion, and the dosage of FK506 was re-
duced. An improvement of renal func-
tion was observed, while rejection per-
sisted but was controlled. In the sec-
ond case, MMF and cyclosporine were
given 11 months after conversion, and
FK506 was withdrawn. The patient
presented a recovery of renal function
without rejection relapse. In 2 other
patients with CR, MMF was initiated
15 and 18 days after conversion due
to a poor biochemical response. In the
first, a rapid biochemical improvement
was observed, while the slow decline
in bilirubin and enzyme levels per-
sisted in the second. In time, both cases
were considered patients who re-
sponded. For the fifth patient who un-
derwent rescue therapy because of an
OKT3-resistant ACR, FK506 plus
MMF were introduced simultaneously
for a more powerful immunosuppres-
sive regimen.
We conclude that FK506 is effec-
tive in rescue therapy of most cases of
acute and chronic rejection in liver
transplantation.
RESUMO
COELHO FF e col. - Uso de tacrolimus
na terapia de resgate de rejeições
agudas e crônicas no transplante de
fígado. Rev. Hosp. Clín. Fac. Med.
S. Paulo 58 (3):141-146, 2003.
OBJETIVO: Estudar os critérios
de indicação e o resultado do uso de
tacrolimus na terapia de resgate de re-
jeições agudas ou crônicas no trans-
plante de fígado.
CASUÍSTICA E MÉTODO: Fo-
ram estudados 18 pacientes transplan-
tados de fígado, submetidos a terapia
de resgate com tacrolimus entre mar-
ço de 1995 e agosto de 1999. Foram
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registradas a indicação do tratamento
e a situação de pacientes e enxertos
em 31/10/1999. Considerou-se “res-
pondendores” pacientes vivos, com
enxerto funcionante e regressão histo-
lógica da terapia de resgate de rejei-
ções agudas, ou com bilirrubina até 2
vezes o valor normal, no caso de tera-
pia de resgate de rejeições crônicas.
RESULTADO: Observou-se res-
posta em 14 casos (77,8%). A taxa de
resposta). Os quatro casos sem respos-
ta (22,2%) evoluíram para óbito.
CONCLUSÃO: O tacrolimus é
eficaz na terapia de resgate da maioria
dos casos de rejeição celular aguda e
crônica no transplante de fígado.
DESCRITORES: Transplante de
fígado. Efeitos adversos. Imunos-
supressão. Tacrolimus. Uso tera-
pêutico.
resposta nas diferentes indicações foi:
(1) terapia de resgate de rejeições agu-
das + sepse bacteriana - 0/1 caso; (2)
terapia de resgate de rejeições agudas
recorrente - 1/1 caso; (3) terapia de res-
gate de rejeições agudas resistente a
OKT3 - 2/2 casos; (4) terapia de res-
gate de rejeições agudas resistente a
corticóide + doença viral ativa - 3/3
casos; (5) terapia de resgate de rejei-
ções crônicas - 8/11 casos (72,7% de
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